many years of research and tests Armenian scientists
at the Institute of Fine Organic Chemistry have
developed compounds they believe will become an
anti-tumor and anti-infection medicine.
For this and other significant research, the
Institute was awarded a Napoleon Bonaparte Gold
Medal by the Societe D'Encouragement Pour L'Industrie
Nationale of France for its cumulative research
in recent years.
And head of the Institute, 65-year old academic
Bagrat Gharibjanyan, was awarded the German Paul
Erlikh Gold medal and Russian Vernadski Silver
medal for exceptional scientific services, and
a Gold medal from SDPL.
"There are very few scientific centers in
the world which implement all the steps starting
from synthesis of the medicine to its production,"
Gharibjanyan says. "The advantage of these
institutions is that all the parts of the process
are combined in the same place. We have chemists,
biologists working here; experiments and technological
investigations are also done here."
According to Gharibjanyan, of the Institute's
18 possible elaborations, it is believed that
compounds exist to aid in anesthetization, dilation
of vessels, regulation of cerebral blood circulation,
peripheral dilation of vessels and anti-tumor
"Pre-clinical tests of some of them are
near to end, three of them need to pass a few-year
clinical tests stage," he says. "Naturally,
we are trying to create such medicine that are
better than the previous ones, are of little harm
for the organism and accessible to patients."
The Institute was founded in 1955 by academician
Armenak Mnjoyan and since has worked toward creating
Instistute, Gharibjanyan says, has developed medicines
that have been used in the treatment of ulcers,
bronchial asthma, Parkinson disease, blood pressure,
typhoid fever, dysentery, epilepsy and others.
"Every medicine produced by the institute
is provided for the efficient treatment of several
diseases," says Gharibjanyan.
But after the collapse of the Soviet Union, the
successes of the Institute stopped. These days
as a result of not having a patent the Institute
is prohibited from exporting production of drugs
to the international markets.
Further, Gharibjanyan says, the process from
raw material to synthetic drug these days cost
more money than was spent during the entire pharmacology
history of the USSR.
In USA only one preparation is taken for preclinical
tests out of 250,000 synthesized preparations.
Then only one of five preparations can be taken
for clinical tests and only one of five preparations
that passed clinical tests can be brought into
"If we multiply all of that it will become
clear what kind of extensive researches must be
conducted to create a drug," says Gharibjanyan.
"Our financial state doesn't allow us to
conduct researches like that, however, guided
by the appropriateness that we established, we
conduct purposeful syntheses, which don't require
But the award-winning scientist says his Institute's
work is largely ignored by companies that could
be beneficial to the Institute's future.
"It hurts that competitive companies don't
consider it expedient to cooperate with us fearing
to acquire strong competitor and fearing to lose
the right of monopolist. The way out is either
to enter Russian markets by means of cooperation
or to find a donor."